Barclays has made an adjustment to BioMarin Pharmaceutical Inc.'s (NASDAQ: NASDAQ:BMRN) stock outlook, lowering the price target to $86 from the previous $110 while maintaining an Overweight rating.
The revision follows the recent Phase 3 data update from competitor Ascendis Pharma (NASDAQ:ASND) regarding its TransCon CNP treatment for achondroplasia, a bone growth disorder.
The Barclays report reflects insights gathered from two key opinion leader (KOL) calls focused on the treatment landscape for achondroplasia and one KOL call on the competitive intellectual property landscape.
According to the feedback, BioMarin maintains a solid IP position in both the EU and the US, with an anticipated royalty of approximately 15-18% if their intellectual property remains intact.
Despite Ascendis Pharma's progress, BioMarin continues to lead in clinical development for hypochondroplasia and other short stature diseases. However, it is expected that Ascendis will likely pursue a similar clinical and development trajectory.
The report indicates that BioMarin's BMN-333 is a crucial factor for the company to maintain its leadership and recapture market share.
The analyst suggests that BMN-333 could potentially exhibit a differentiated clinical profile due to its unique approach to extending CNP half-life compared to TransCon CNP. The report anticipates that BMN-333 could enter the market by late 2029 or early 2030, trailing TransCon CNP by approximately three to four years.
In other recent news, BioMarin Pharmaceutical Inc. reported record total revenue of $712 million and adjusted its full-year revenue guidance to between $2.75 billion and $2.825 billion. The company's ambitious financial targets for 2027 include a revenue goal of $4 billion and non-GAAP operating margins in the low-to-mid 40% range.
Goldman Sachs maintained a Buy rating on BioMarin, citing confidence in the company's ability to achieve these targets despite increasing competition in the treatment of achondroplasia. The firm's confidence is bolstered by the growing penetration of BioMarin's Voxzogo in the U.S. market, which benefits from a broad label and no lower age restriction.
Various analyst firms have adjusted their outlooks for BioMarin. Citi maintained its Neutral stance with a $93 price target, while Scotiabank reduced its price target to $78 due to competitive risks. Truist Securities cut its price target to $90, but kept a Buy rating, and RBC Capital reduced BioMarin's price target to $85 with a Sector Perform rating.
BioMarin's leadership, including President and CEO Alexander Hardy and EVP and CFO Brian Mueller, highlighted the company's strong patent position and its potential for growth. This includes the expansion of Voxzogo into new geographies and an optimized enzyme replacement business.
InvestingPro Insights
BioMarin Pharmaceutical's recent market performance aligns with Barclays' revised outlook. According to InvestingPro data, the company's stock has experienced a significant decline, with a 24.15% drop in the past month and a 29.31% decrease year-to-date. This downward trend is reflected in the stock trading near its 52-week low, as highlighted by one of the InvestingPro Tips.
Despite these challenges, BioMarin's fundamentals show some positive signs. The company's revenue growth of 15.83% over the last twelve months and a 19.61% increase in quarterly revenue suggest ongoing business expansion, which could support its market position in the competitive achondroplasia treatment landscape. Additionally, an InvestingPro Tip indicates that net income is expected to grow this year, potentially bolstering the company's financial health as it navigates market competition.
Investors should note that BioMarin is trading at a P/E ratio of 50.29, which an InvestingPro Tip describes as a high earnings multiple. However, another tip suggests the stock is trading at a low P/E ratio relative to near-term earnings growth, with a PEG ratio of 0.33, indicating potential undervaluation considering its growth prospects.
For a more comprehensive analysis, InvestingPro offers 14 additional tips for BioMarin Pharmaceutical, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.